Pre‐treatment wait time for head and neck cancer patients in Western Australia: description of a new metric and examination of predictive factors

Abstract

Background Prolonged pre‐treatment wait times in head and neck cancer are associated with increased morbidity and reduced survival. Traditional metrics exclude delays prior to biopsy, which represents an important and measurable period of time. This study aims to describe total wait time for head and neck cancer patients in our institution, to define a more accurate representation of the clinically relevant pre‐treatment wait time, and to evaluate predictive factors for prolonged wait times. Methods A retrospective review of head and neck cancer patients treated over 2 years in a tertiary referral centre was conducted. Patient demographics, referral symptoms, tumour details, treatment plan and key dates were analysed to identify total wait time and factors predictive of increased wait time. Results Two hundred and ninety‐four patients were included. Mean total wait time from initial referral to treatment initiation was 71.6 (median 61) days. The period from referral to biopsy represented 29% of mean total wait time. Factors predictive of increased wait time included presenting symptom of hoarseness, laryngeal cancer and treatment with definitive radiotherapy. Conclusions This study demonstrates that time from referral to biopsy represents a significant portion of total wait time, and we suggest that this be incorporated into future wait time metrics for improved clinical relevance. Furthermore, we have identified factors predicting increased wait time which can be targeted for future service improvement.

Influence of remoteness of residence on timeliness of diagnosis and treatment of oral cavity and oropharynx cancer: A retrospective cohort study

“…Our findings compare with previous Australian literature, particularly that increasing remoteness of residence is associated with longer intervals to diagnosis and treatment, but not overall survival . Recently, Flukes et al . showed that 46% of HNC patients in Western Australia met the Australian benchmark of commencing treatment within 56 days of referral to a specialist.…”

“…Additional intervals that apply to a greater proportion of HNC patients should also be considered. For example, Flukes et al . suggest a new metric of referral (to a specialist) to biopsy.…”

Seeking Medical Assistance for Dysphonia Is Associated with an Improved Survival Rate in Laryngeal Cancer: Real-World Evidence

“…In cases of laryngeal cancers that originate in the supra-or subglottis, the voice change happens when the tumor invades the glottic area [14]. Thus, dysphonia in supra-or subglottic cancer does not warn patients when tumor is small unlike the voice symptoms leading to the early detection of patients with glottic cancer [16]. The dysphonia symptoms influence patients' outcomes more in glottic cancer than other subsites of laryngeal cancer [17].…”

Introduction of surgeon‐performed ultrasound to a head and neck clinic: indications, diagnostic adequacy and a new clinic model?

“…A recent publication raised concern that wait time to tissue biopsy is an important rate‐limiting step in time to treatment for all head and neck cancers . The SMAHT clinic aims to streamline patient diagnosis, circumvent inefficiency of wait‐times and reduce anxiety and multiple appointments that surround radiology‐performed US‐FNA (for a weekly clinic that services local, state‐wide, interstate and international patients).…”